COVID-19 rebound after oral treatment in a nursing home facility: A case series
Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2–8 days after completing the treatment cour...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2022-12-01
|
| Edice: | Infectious Medicine |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2772431X22000521 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|